Vanguard Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,565,044
| Closed | -$71.8M | – | 4465 |
|
|
2024
Q1 | $71.8M | Buy |
4,565,044
+163,408
| +4% | +$2.52M | ﹤0.01% | 2018 |
|
|
2023
Q4 | $71M | Buy |
4,401,636
+33,203
| +0.8% | +$424K | ﹤0.01% | 2035 |
|
|
2023
Q3 | $55.6M | Sell |
4,368,433
-23,837
| -0.5% | -$329K | ﹤0.01% | 2080 |
|
|
2023
Q2 | $61.8M | Sell |
4,392,270
-218,820
| -5% | -$3.13M | ﹤0.01% | 2091 |
|
|
2023
Q1 | $71.2M | Sell |
4,611,090
-134,231
| -3% | -$2.24M | ﹤0.01% | 2002 |
|
|
2022
Q4 | $77.8M | Sell |
4,745,321
-49,672
| -1% | -$808K | ﹤0.01% | 1945 |
|
|
2022
Q3 | $88.7M | Buy |
4,794,993
+402,047
| +9% | +$6.31M | ﹤0.01% | 1863 |
|
|
2022
Q2 | $57.8M | Buy |
4,392,946
+798,434
| +22% | +$8.81M | ﹤0.01% | 2129 |
|
|
2022
Q1 | $33.3M | Buy |
3,594,512
+125,195
| +4% | +$1.06M | ﹤0.01% | 2521 |
|
|
2021
Q4 | $33.9M | Sell |
3,469,317
-467,068
| -12% | -$8.78M | ﹤0.01% | 2560 |
|
|
2021
Q3 | $134M | Buy |
3,936,385
+8,681
| +0.2% | +$277K | ﹤0.01% | 1817 |
|
|
2021
Q2 | $144M | Sell |
3,927,704
-20,358
| -0.5% | -$788K | ﹤0.01% | 1810 |
|
|
2021
Q1 | $177M | Buy |
3,948,062
+112,304
| +3% | +$5.23M | ﹤0.01% | 1649 |
|
|
2020
Q4 | $219M | Buy |
3,835,758
+61,497
| +2% | +$3.65M | 0.01% | 1412 |
|
|
2020
Q3 | $194M | Buy |
3,774,261
+224,700
| +6% | +$11M | 0.01% | 1303 |
|
|
2020
Q2 | $212M | Buy |
3,549,561
+1,034,589
| +41% | +$55.3M | 0.01% | 1239 |
|
|
2020
Q1 | $104M | Buy |
2,514,972
+314,211
| +14% | +$17.4M | ﹤0.01% | 1508 |
|
|
2019
Q4 | $137M | Buy |
2,200,761
+757,527
| +52% | +$36M | ﹤0.01% | 1594 |
|
|
2019
Q3 | $49M | Buy |
1,443,234
+650,580
| +82% | +$19.3M | ﹤0.01% | 2076 |
|
|
2019
Q2 | $17.9M | Buy |
792,654
+20,252
| +3% | +$474K | ﹤0.01% | 2568 |
|
|
2019
Q1 | $17.9M | Buy |
772,402
+59,240
| +8% | +$1.55M | ﹤0.01% | 2555 |
|
|
2018
Q4 | $15M | Buy |
713,162
+37,645
| +6% | +$925K | ﹤0.01% | 2579 |
|
|
2018
Q3 | $26.2M | Buy |
675,517
+14,081
| +2% | +$520K | ﹤0.01% | 2459 |
|
|
2018
Q2 | $26M | Buy |
661,436
+335,553
| +103% | +$9.88M | ﹤0.01% | 2448 |
|
|
2018
Q1 | $6.53M | Buy |
325,883
+35,225
| +12% | +$892K | ﹤0.01% | 3034 |
|
|
2017
Q4 | $6.59M | Buy |
290,658
+108,658
| +60% | +$2.13M | ﹤0.01% | 3022 |
|
|
2017
Q3 | $3.46M | Buy |
+182,000
| New | +$3.33M | ﹤0.01% | 3244 |
|
Other funds holding DCPH
Vanguard Group's DCPH Position: Q2 2024 in Review
Vanguard Group sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 4,565,044 shares — an estimated $71.8M sold.
Vanguard Group first reported a position in DCPH in Q3 2017 and held it in 27 quarters. The position peaked at $219M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Vanguard Group reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Vanguard Group sold 4,565,044 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $71.8M.
- Vanguard Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 27 quarters.
- Vanguard Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $219M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.